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Malignant hyperthermia (MH) is an inherited pharmacogenetic disorder characterised by accelerated metabolism and rigidity in skeletal muscle. MH occurs in susceptible subjects after exposure to triggering agents such as inhalational anaesthetics and depolarising muscle relaxants.' The incidence of MH has been estimated at 1 in 50 000 to 75 000 anaesthetised patients in the UK (unpublished data from the UK Malignant Hyperthermia Investigation Unit, Leeds). Other studies indicate a higher incidence than this of 1 in 10 000, especially in childhood, which may reflect the reduced penetrance of MHS with increasing age.24
Clinical malignant hyperthermia A family in which 10 deaths occurred as a result of general anaesthesia for minor surgery has been described. 5 Linkage studies in the pig have also shown tight linkage between polymorphisms detected by the CRC (R YR1) cDNA and PSS, with no recombinants detected.3>36 The sequence of the CRC cDNA in halothane positive and negative animals was compared and these studies detected 18 base substitutions, only one of which resulted in an altered amino acid.37 This mutation (C-T at nucleotide 1843) leads to Arg6'5 being substituted for Cys and was found in all of more than 450 positive animals from six PSS susceptible breeds.
The same mutation at the DNA level has been detected in one Canadian MH family out of over 50 tested.38 This clearly reflects the differences between the highly inbred pig population, where a single mutation has become fixed by selective breeding, and the human population where locus heterogeneity is expected. Indeed, it has been suggested that the mutation predisposing to MHS also predisposed towards increased muscle mass. '3 As a result the Hal mutation may have been subjected to powerful selection by pig breeders and transmitted to all six pig breeds in which it has been found from a single ancestral mutation. Indeed the large size of the CRC gene ( > 250 kb) makes it likely that many different mutations in the CRC gene could give rise to the MHS phenotype.
Heterogeneity in MH While there are clearly linkage and mutation data supporting the skeletal muscle CRC as the site of the primary defect in some MHS subjects, a growing number of non-chromosome 19q13.1 linked families have been reported.342 In these studies a number of large pedigrees in which MHS is segregating have been shown by genetic recombination to exclude linkage to the region of the CRC gene on 19q. At a meeting of the EMHG Genetics Section in January 1992 a survey showed that eight out of 15 large families from within the group showed exclusion with markers from 19q13. 1-13.2. Therefore, for approximately 50% of European families genetic diagnosis with markers from this region is contraindicated. However, where family structure permits the clear demonstration of linkage to the CRC gene, or closely flanking markers, with a lod score greater than 3 within that family, genetic diagnosis can and has been performed.43 A summary of the most informative markers used in all of these studies is shown in the figure.
It is well documented that the MHS phenotype, as detected by the in vitro contracture test, can arise secondarily in patients with other neuromuscular diseases. These include myotonic dystrophy (DM),44 myotonia congenita,45 Duchenne and Becker muscular dystrophy (DMD and BMD),4 and central core disease (CCD).47 These conditions are clinically and genetically distinct from one another although the loci for DM and CCD also map to chromosome 19q. It is well established that 
